

MOJGAN GHARIPOUR CURRICULUM VITAE

A. PERSONAL INFORMATION:

1. **Name:** Mojgan Gharipour
 2. **Citizenship:** Iranian
 3. **Address:** Department of Genetic Studies, Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Science, Isfahan, Iran
 4. **Mobile Phone:** +98 913 103 0177
 5. **Research Gate:** https://www.researchgate.net/profile/Mojgan_Gharipou
Res.
 6. **Google scholar:** <https://scholar.google.com/citations?user=E1Pb6VYAAAAJ&hl=en&oi=ao>
 7. **ORCID:** <https://orcid.org/0000-0001-7397-1172>
-

B. EDUCATION:

2018: Visiting fellowship in the Epigenetic, Seoul National University, Seoul, Korea

2017: PhD. Biomedical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran (GPA: A+)

Title of my PhD thesis: Function of SELENOP and SELENOS in the DNA, RNA and protein levels in patients with metabolic syndrome and history of coronary artery disease: Selenogene Study in collaboration with Nantes University (France)

2000: Master of Science in Clinical Biochemistry, School of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran (GPA: A+)

1996: Bachelor of Biology, School of Basic Sciences, Isfahan University, Isfahan, Iran (GPA: A)

MOJGAN GHARIPOUR

CURRICULUM VITAE

C. HONORS & AWARDS:

- **2019** Distinguished Researcher Isfahan Cardiovascular Research Center. 2019; December, Isfahan, Iran.
- **2014** First Place Winner of Oral Presentation, The first NCD Congress in the UAE.2014; January 9 -11, Dubai, EUA.
- **2013** Travel Grant Winner as Nominated Young Investigator, 24th Scientific Meeting of the International Society of Hypertension, 2013; September 30 to October 4, Sydney, Australia.
- **2012** Young Investigator Grant Winner as Nominated Young Investigator, World Congress of Cardiology in Dubai. 2012; April 17-21, Dubai, EUA.
- **2012** Brilliant Researcher in Medical Sciences, Provincial Governor, 2012; December 20, Isfahan, Iran.
- **2012** Travel Grants Winner as Nominated Young Investigator, 22nd European Meeting on Hypertension in London. 2012; June 17-21, London, UK.
- **2012** First Place Winner of Invention and Research, Isfahan Cardiovascular Research Institute.2012; October 30, Isfahan, Iran.
- **2011** Travel Grant Winner as Nominated Young Investigator, 21st European Meeting on Hypertension. 2011; June 17-21, Milan, Italy.
- **2010** First Place Winner of Invention and Research, Isfahan Cardiovascular Research Center. 2011; October, Isfahan, Iran.
- **2010** Travel Grant Winner as Nominated Young Investigator, 20th European Meeting on Hypertension. 2010; June 18-21, Oslo, Norway.

D. PUBLICATIONS & PRESENTATIONS:

MOJGAN GHARIPOUR

CURRICULUM VITAE

- 1) Vaseghi G, Malakoutikhah Z, Shafiee Z, Gharipour M, Shariati L, Sadeghian L, Khosravi E, Javanmard SH, Pourmoghaddas A, Laher I, Zarfeshani S, Sarrafzadegan N. Apolipoprotein B gene mutation related to familial hypercholesterolemia in an Iranian population: With or without hypothyroidism. *J Res Med Sci*. 2021 Oct 18;26:94. doi: 10.4103/jrms.JRMS_970_19.
- 2) Gharipour M, Mani A, Amini Baghbahadorani M, de Souza Cardoso CK, Jahanfar S, Sarrafzadegan N, de Oliveira C, Silveira EA. How Are Epigenetic Modifications Related to Cardiovascular Disease in Older Adults? *Int J Mol Sci*. 2021 Sep 14;22(18):9949. doi: 10.3390/ijms22189949
- 3) Gharipour M, Behmanesh M, Salehi M, Vaseghi G, Nezafati P, Dianatkah M, Khosravi E, Hosseini M, Sadeghi M. Association of Selenoprotein S Expression and its Variants with Metabolic Syndrome in Subjects with Cardiovascular Disease. *Arch Med Res*. 2020 Aug;51(6):535-541. doi: 10.1016/j.arcmed.2020.05.005.
- 4) Sabri MR, Gharipour M, Tayebi N, Sadeghian L, Javanmard SH, Sarrafzadegan N. Determining genetic variants in children and adolescents suffering from tetralogy of Fallot with a positive family history: methodology. *Acta Biomed*. 2020 Jun 26;91(4): e2020096. doi: 10.23750/abm.v91i4.8410.
- 5) Ahmadi A, Gharipour M, Navabi ZS, Heydari H. Risk factors of congenital heart diseases: A hospital-based case-control study in Isfahan, Iran. *ARYA Atheroscler*. 2020 Jan;16(1):1-6. doi: 10.22122/arya.v16i1.1941.
- 6) Gharipour A, Razavi R, Gharipour M, Mukasa D. Lactate/albumin ratio: An early prognostic marker in critically ill patients. *Am J Emerg Med*. 2020 Jun 27;38(10):2088-2095. doi: 10.1016/j.ajem.2020.06.067.
- 7) Gharipour M, Berekatain M, Sung J, et al. The Epigenetic Overlap between Obesity and Mood Disorders: A Systematic Review. *Int J Mol Sci*. 2020;21(18): E6758.
- 8) Ahmadi A, Gharipour M, Navabi ZS, Heydari H. Risk Factors of Congenital Heart Diseases: A Hospital-Based Case-Control Study in Isfahan, Iran. *ARYA Atheroscler*. 2020;16(1):1-6.
- 9) Gharipour M, Behmanesh M, Salehi M, et al. Association of Selenoprotein S expression and its variants with metabolic syndrome in subjects with cardiovascular disease. *Arch Med* 2020; s0188-44091(9)30435-7.
- 10) Gharipour A, Razavi R, Gharipour M, Modarres R, Nezafati P, Mirkheshti N. The incidence and outcome of severe hyperlactatemia in critically ill patients. *Intern Emerg Med*. 2020;10.1007/s11739-020-02337-9.
- 11) Razavi R, Gharipour A, Gharipour M. Depression screening using mobile phone usage metadata: a machine learning approach. *J Am Med Inform Assoc*. 2020; ocz221.
- 12) Gharipour M, Sadeghi M, Nezafati P, Dianatkah M, Sarrafzadegan N. Cardiovascular disease risk assessment: triglyceride/high-density lipoprotein versus metabolic syndrome criteria. *J Res Health Sci*. 2019;19(2): e00442.
- 13) Gharipour M, Ouguerram K, Nazih EH, Salehi M, Behmanesh M, Razavi R, Gharipour, A, Dianatkah M, Sadeghi M. Effect of single nucleotide polymorphisms in SEPS1 and SEPP1 on expression in the protein level in metabolic syndrome in subjects with cardiovascular disease. *Mol Biol Rep*. 2019; Sep 21.
- 14) Sadeghi M, Talaei M, Gharipour M, Oveisgharan S, Nezafati P, Sarrafzadegan N. Anthropometric indices predicting incident hypertension in an Iranian population: The Isfahan cohort study. *Anatol J Cardiol*. 2019 Jun; 22(1): 33-43.

MOJGAN GHARIPOUR CURRICULUM VITAE

- 15) Kiani K, Roohafza H, **Gharipour M**, Dianatkah M, Talaei M, Oveisgharan S, Sarrafzadegan N, Sadeghi M. The association between the serum 25-hydroxyvitamin D level and cardiovascular events in individuals with and without metabolic syndrome. *ARYA Atheroscler*. 2018 Nov;14(6):254-259.
- 16) Khosravi A, Mohammadifard N, **Gharipour M**, Abdollahi Z, Nouri F, Feizi A, Jozan M, Sarrafzadegan N. Low correlation between morning spot and 24-hour urinesamples for estimating sodium intake in an Iranian population: Isfahan Salt Study. *Int J Vitam Nutr Res*. 2019 Mar 19: 1-7.
- 17) **Gharipour M**, Sadeghi M, Behmanesh M, Salehi M, Roohafza H, Nezafati P, Khosravi E, Hosseini M, Keshvari M, Rouhi-Bourojeni H, Sarrafzadegan N. Proposal of a study protocol of a preliminary double-blind randomized controlled trial, verifying effects of selenium supplementation on selenoprotein p and s genes expression in protein and mRNA levels in subjects with coronary artery disease: selenogene. *Acta Biomed*. 2019 Jan 22; 90(1): 44-50.
- 18) Pourmoghdas A, **Gharipour M**, Garakyaraghi M, Nouri F, Taheri M, Sadeghi M. Association of socioeconomic status and hypertension based on habitual smoking among Iranian population: IHHP study. *Acta Biomed*. 2019 Jan 15;89(4):498-504.
- 19) Eishi Oskouei A, Rafiee L, Mahzouni P, **Gharipour M**, Javanmard SH. Association between autocrine motility factor receptor gene polymorphism (rs2440472, rs373191257) and glioblastoma multiform in a representative Iranian population. *J Res Med Sci*. 2018 Nov 28; 23: 96.
- 20) Mirmohammadsadeghi A, **Gharipour M**, Roohafza H, Dianatkah M, Sadeghi M. Effects of selenium supplementation on paraoxonase-1 and myeloperoxidase activity in subjects with cardiovascular disease: The Selenogene study, a double-blind randomized controlled trial. *Arch Med Sci Atheroscler Dis*. 2018 Aug 24; 3: e112-e118.
- 21) Esfahani BN, Kolahdouzan M, Aflakseir A, **Gharipour M**. Predicting body mass index in women: The value of the psychological components of depression, anxiety, dietary restraint, and nutritional habits. *J Educ Health Promot*. 2017 Apr 19; 6:9.
- 22) **Gharipour M**, Ouguerram K, Nazih EH, Salehi M, Behmanesh M, Roohafza H, Hosseini SM, Nezafati P, Dianatkah M, Gharipour A, Haghjoo S, Sarrafzadegan N, Sadeghi M. Effects of selenium supplementation on expression of SEPP1 in mRNA and protein levels in subjects with and without metabolic syndrome suffering from coronary artery disease: Selenogene study a double-blind randomized controlled trial. *J Cell Biochem*. 2018 Jun 22; 119(10): 8282-8289.
- 23) Rouhi-Boroujeni H, Heidarian E, Rouhi-Boroujeni H, Khoddami M, **Gharipour M**, Rafieian-Kopaei M. Use of lipid-lowering medicinal herbs during pregnancy: A systematic review on safety and dosage. *ARYA Atheroscler*. 2017 May; 13(3): 135-155.
- 24) **Gharipour M**, Sadeghi M, Behmanesh M, Salehi M, Nezafati P, Gharipour A. Selenium homeostasis and clustering of cardiovascular risk factors: a systematic review. *Acta Biomed*. 2017 Oct 23;88(3): 263-270.
- 25) Rouhi-Boroujeni H, Hosseini M, **Gharipour M**, Rouhi-Boroujeni H. Is herbal therapy safe in obesity? A case of *Apium graveolens* (Celery) induced hyperthyroidism. *ARYA Atheroscler*. 2016 Sep; 12(5): 248-249.

MOJGAN GHARIPOUR CURRICULUM VITAE

- 26) Esfahani MA, **Gharipour M**, Fesharakinia H. Changes in intraocular pressure after exercise test. *Oman J Ophthalmol.* 2017 Jan-Apr;10(1):17-20.
- 27) **Gharipour M**, Sadeghi M, Salehi M, Behmanesh M, Khosravi E, Dianatkah M, Haghjoo Javanmard S, Razavi R, Gharipour A. Association of expression of selenoprotein P in mRNA and protein levels with metabolic syndrome in subjects with cardiovascular disease: results of the selenogene study. *J Gene Med.* 2017; Mar;19(3).
- 28) **Gharipour M**, Sadeghi M, Nouri F, Nezafati P, Qader SS, Taheri M, Maghroun M, Abdalvand A, Soleimani B, Sarrafzadegan N. Socioeconomic determinants and metabolic syndrome: results from the Isfahan Healthy Heart Program. *Acta Biomed.* 2017 Jan 16; 87(3): 291-198.
- 29) Sadeghi M, **Gharipour M**, Nezafati P, Shafie D, Aghababaei E, Sarrafzadegan N. Assessing metabolic syndrome through increased heart rate during exercise. *Acta Med Iran.* 2016 Nov; 54(11): 724-730.
- 30) Khosravi A, Ahmadzadeh S, **Gharipour M**, Golshahi J, Sadeghi M, Jozan M, Sarrafzadegan N. Is there any relationship between different phenotypes of metabolic syndrome and cardiovascular mortality rate? *Adv Biomed Res.* 2016 Nov 28; 5:185.
- 31) Sarrafzadegan N, **Gharipour M**, Sadeghi M, Nezafati P, Talaie M, Oveisgharan S, Nouri F, Khosravi A. Metabolic syndrome and the risk of ischemic stroke. *J Stroke Cerebrovasc Dis.* 2017 Feb; 26(2): 286-294.
- 32) Sheikhbahaie F, Amini M, **Gharipour M**, Aminoroaya A, Taheri N. The effect of hydroxychloroquine on glucose control and insulin resistance in the prediabetes condition. *Adv Biomed Res.* 2016 Aug 30; 5:145.
- 33) Khosravi A, **Gharipour M**, Behjati M, Sadeghi M, Nezafati P, Talaie M, Shirani S, Jozan M. Paternal or maternal history of hypertension is more important in increasing the risk of hypertension in offspring? *Acta Biomed.* 2016 Sep13; 87(2): 161-7.
- 34) Khosravi A, **Gharipour M**, Nezafati P, Khosravi Z, Sadeghi M, Khaledifar A, Taheri M, Golshahi J, Sarrafzadegan N. Pre-hypertension, pre-diabetes or both: which is best at predicting cardiovascular events in the long term? *J Hum Hypertens.* 2017 Jun; 31(6): 382-387.
- 35) **Gharipour M**, Sadeghi M, Dianatkah M, Nezafati P, Talaie M, Oveisgharan S, Golshahi J. Comparison between European and Iranian cutoff points of triglyceride/high-density lipoprotein cholesterol concentrations in predicting cardiovascular disease outcomes. *J Clin Lipidol.* 2016 Jan-Feb; 10(1):143-9.
- 36) Hashemi Jazi M, Nilforoush P, **Gharipour M**, Batvandi A, Mohammadi R, Najafi R. Main clinical determinants of the presence of coronary artery disease in patients with left bundle branch block. *Acta Biomed.* 2015 Dec 15; 86(3): 267-72.
- 37) Khosravi A, Gharipour A, **Gharipour M**, Khosravi M, Andalib E, Shirani S, Mirmohammad Sadeghi M. Advanced method used for hypertension's risk factors stratification: support vector machines and gravitational search algorithm. *ARYA Atheroscler.* 2015 Nov;11(6): 349-56.
- 38) **Gharipour M**, Hashemi Jazi M, Nilforoush P, Batvandi A, Mohammadi R, Najafi R. Metabolic syndrome and its association with left ventricular dysfunction in patients with left bundle branch block. *Acta Biomed.* 2015 Sep 14; 86(2):157-61.

MOJGAN GHARIPOUR CURRICULUM VITAE

- 39) Rouhi-Boroujeni H, Rouhi-Boroujeni H, **Gharipour M**, Mohammadzadeh F, Ahmadi S, Rafieian-Kopaei M. Systematic review on safety and drug interaction of herbal therapy in hyperlipidemia: a guide for internist. *Acta Biomed.* 2015 Sep14; 86(2): 130-6.
- 40) Nezafati P, **Gharipour M**, Nezafati MH. Surgical ablation for atrial fibrillation: an editorial. *J Thorac Dis.* 2015 Aug; 7(8): E239-42.
- 41) **Gharipour M**, Sadeghi MM, Sadeghi M, Farhmand N, Sadeghi PM. Detrimental predictive effect of metabolic syndrome on postoperative complications in patients who undergoing coronary artery bypass grafting. *Acta Biomed.* 2015 Apr 27; 86(1): 86-91.
- 42) Khaledifar A, **Gharipour M**, Bahonar A, Sarrafzadegan N, Khosravi A. Association between dietary salt intake and reservation of renal function in patients with mild hypertension. *ARYA Atheroscler.* 2015 Feb;11(Suppl 1): 69-73.
- 43) Hashemi Jazi M, Nilforoush P, **Gharipour M**, Batvandi A, Mohammadi R, Najafi R. Clinical determinants of left ventricular ejection fraction deterioration in patients suffered from complete left bundle branch block. *Iran Red Crescent Med J.* 2015 Feb 21;17(2): e16570.
- 44) **Gharipour M**, Sadeghi M, Hosseini M, Andalib E, Boroujeni MB, Sarrafzadegan N. Effect of age on the phenotype of metabolic syndrome in developing country. *Adv Biomed Res.* 2015 May 29; 4:103.
- 45) **Gharipour M**, Sarrafzadegan N, Sadeghi M, Khosravi A, Hoseini M, Khosravi-Boroujeni H, Khaledifar A. The metabolic syndrome and associated lifestyle factors among the Iranian population. *Adv Biomed Res.* 2015 May 11; 4: 84.
- 46) **Gharipour M**, Sadeghi MM, Sadeghi M, Farhmand N, Sadeghi PM. Detrimental predictive effect of metabolic syndrome on postoperative complications in patients who undergoing coronary artery bypass grafting. *Acta Biomed.* 2015 Apr 27; 86(1): 86-91.
- 47) **Gharipour M**, Bahonar A, Sarrafzadegan N, Khosravi A, Khaledifar A. Are there any differences in education levels and changes of cardiovascular risk factors among urban and rural population: Isfahan Healthy Heart Program? *J Educ Health Promot.* 2015 Mar 27; 4: 24.
- 48) Khosravi A, Pourheidar B, Roohafza H, Moezzi M, Mousavi M, Hajiannejad A, Bidram P, **Gharipour M**, Shirani S, Golshahi J, Boshtam M, Sarrafzadegan N. Evaluating factors associated with uncontrolled hypertension: Isfahan cohort study, Iran. *ARYA Atheroscler.* 2014 Nov;10(6): 311-8.
- 49) Mirdamadi A, Dashtkar S, Kaji M, Pazhang F, Haghpanah B, **Gharipour M**. Dabigatran versus Enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: A randomized clinical trial. *ARYA Atheroscler.* 2014 Nov;10(6):292-7.
- 50) Khosravi A, **Gharipour M**, Isfahani MA, Mohajeri H, Saadatnia M, Roghani F, Shirani S, Khaledifar A. Perspective on the hospital incidence rate of deep venous coagulopathy: Clinical and biochemical diagnostic markers. *Adv Biomed Res.* 2014 Dec 12; 3:254.
- 51) Sadeghi MM, Hashemi M, Rabbani M, **Gharipour M**, Nilfroush P, Majidi E, Farahamand N, Sadeghi PM. Which technique is suitable for management of acute myocardial infarction following coronary artery bypass

MOJGAN GHARIPOUR CURRICULUM VITAE

- surgery, rescue percutaneous coronary intervention or open heart surgery? A case-series study. *Acta Biomed.* 2014 Dec 17; 85(3): 277-80.
- 52) Toghianifar N, Sarrafzadegan N, **Gharipour M.** Women's attitude toward smoking: effect of a community-based intervention on smoking-related social norms. *Int J Evid Based Healthc.* 2014 Dec;12(4): 262-6.
- 53) Bayanfar Z, Sadeghi M, Heidari R, Gharipour M, Talaie M, Sedaghat A. Carotid intima-media thickness and plasma fibrinogen among subjects with metabolic syndrome: Isfahan cohort study, Iran. *ARYA Atheroscler.* 2014 Sep;10(5): 238-43.
- 54) Ahmadi A, Sabri M, Hashemi M, **Gharipour M.** Transcatheter occlusion of patent ductus arteriosus: success rate and complications 5 years' experience: single center in Isfahan. *Acta Biomed.* 2014 Aug 20; 85(2): 116-20.
- 55) Ahmadi A, **Gharipour M.**, Nouri F, Kelishadi R, Sadeghi M, Sarrafzadegan N. Association between adolescence obesity and metabolic syndrome: Evidence from Isfahan Healthy Heart Program. *Indian J Endocrinol Metab.* 2014 Jul; 18(4): 569-73.
- 56) Ahmadi A, **Gharipour M.**, Arabzadeh G, Moin P, Hashemipour M, Kelishadi R. The effects of vitamin E and omega-3 PUFAs on endothelial function among adolescents with metabolic syndrome. *Biomed Res Int.* 2014; 2014: 906019.
- 57) Mirdamadi A, Garakyaraghi M, Pourmoghaddas A, Bahmani A, Mahmoudi H, **Gharipour M.** Beneficial effects of testosterone therapy on functional capacity, cardiovascular parameters, and quality of life in patients with congestive heart failure. *Biomed Res Int.* 2014; 2014: 392432.
- 58) Ahmadi A, Sabri M, Bigdelian H, Dehghan B, **Gharipour M.** Comparison of cost-effectiveness and postoperative outcome of device closure and open surgery closure techniques for treatment of patent ductus arteriosus. *ARYA Atheroscler.* 2014 Jan; 10(1): 37-40.
- 59) Sajjadi F, **Gharipour M.**, Mohammadifard N, Nouri F, Maghroun M, Alikhasi H. Relationship between legumes consumption and metabolic syndrome: findings of the Isfahan Healthy Heart Program. *ARYA Atheroscler.* 2014 Jan; 10(1): 18-24.
- 60) Sadeghi M, Khosravi-Boroujeni H, Sarrafzadegan N, Asgary S, Roohafza H, **Gharipour M.**, Sajjadi F, Khalesi S, Rafieian-Kopaei M. Cheese consumption in relation to cardiovascular risk factors among Iranian adults: IHHP Study. *Nutr Res Pract.* 2014 Jun; 8(3): 336-41.
- 61) **Gharipour M.**, Sadeghi M, Dianatkah M, Bidmeshgi S, Ahmadi A, Tahri M, Sarrafzadegan N. The cut-off values of anthropometric indices for identifying subjects at risk for metabolic syndrome in Iranian elderly men. *J Obes.* 2014; 2014: 907149.
- 62) Golshahi J, Nasri H, Gharipour M. Contrast-induced nephropathy; a literature review. *J Nephropatho.* 2014; 3(2): 51-56.
- 63) Emami M, Tayebi A, **Gharipour M.**, Farzammia S, Temyarti AK. Comparing clinical efficacy of Symbicort versus Pulmicort in reducing asthma symptom and improving its control. *Adv Bio Res.* 2014 Feb 28; 3: 86.

MOJGAN GHARIPOUR CURRICULUM VITAE

- 64) Rafieian-Kopaei M, Shahinfard N, Rouhi-Boroujeni H, **Gharipour M**, Darvishzadeh-Boroujeni P. Effects of *Ferulago angulata* extract on serum lipids and lipid peroxidation. *Evid Based Complement Alternat Med*. 2014; 2014: 680856.
- 65) **Gharipour M**, Sadeghi M. Pivotal role of microRNA-33 in metabolic syndrome: a systematic review. *ARYA Atheroscler*. 2013 Nov; 9(6): 372-6.
- 66) Hemmati R, **Gharipour M**, Khosravi A, Jozan M. A cost-benefit and accurate method for assessing microalbuminuria: single versus frequent urine analysis. *Int J Hypertens*. 2013; 2013: 752903.
- 67) Bahreini N, **Gharipour M**, Khosravi-Boroujeni H, Rouhi-Boroujeni H, Shiranian A, Salehi-Abargouei A, Sharifzadeh G. Pivotal role of Mediterranean dietary regimen in the increase of serum magnesium concentration in patients with coronary artery disease. *J Nut Met*. 2013; 431070.
- 68) Khaledifar A, **Gharipour M**, Bahonar A, Sarrafzadegan N, Khosravi A. association between salt intake and albuminuria in normotensive and hypertensive individuals. *Int J Hypertens*. 2013; 2013:523682.
- 69) **Gharipour M**, Ramezani MA, Sadeghi M, Khosravi A, Masjedi M, Khosravi-Boroujeni H, Rafieian- Kopaei M, Sarrafzadegan N. Sex based levels of C-reactive protein and white blood cell count in subjects with metabolic syndrome: Isfahan Healthy Heart Program. *J Res Med Sci* 2013; 18(6):467-72.
- 70) Sabri MR, Daryoushi H, **Gharipour M**. Endothelial function state following repair of cyanotic congenital heart diseases. *Cardiol Young*. 2013; 29:1-6.
- 71) Kiani A, Mirmohammad-Sadeghi M, **Gharipour M**, Farahmand N. Preconditioning by Isoflurane as a volatile anesthetic in elective coronary artery bypass surgery. *ARYA Atheroscler*. 2013; 9(3):192-7.
- 72) **Gharipour M**, Ramezani MA, Sadeghi M, Khosravi A, Masjedi M, Khosravi-Boroujeni H, Rafieian- kopaei M, Sarrafzadegan N. Sex based levels of C-reactive protein and white blood cell count in subjects with metabolic syndrome: Isfahan Healthy Heart Program. *J Res Med Sci*. 2013; 18 (6): 467-472.
- 73) Ahmadi A, **Gharipour M**, Nouri F, Sarrafzadegan N. Metabolic syndrome in Iranian youths: a population-based study on junior and high school's students in rural and urban areas. *J Diab Res*.2013; 2013: 738485.
- 74) **Gharipour M**, Sarrafzadegan N, Sadeghi M, Andalib E, Talaie M, Shafie D, Aghababaie E. Predictors of metabolic syndrome in the Iranian population: waist circumference, body mass index, or waist to hip ratio? *Cholesterol*. 2013; 2013:198384.
- 75) **Gharipour M**, Khosravi A, Sadeghi M, Roohafza H, Hashemi M, Sarrafzadegan N. Socioeconomic characteristics and controlled hypertension: Evidence from Isfahan Healthy Heart Program. *ARYA Atheroscler*. 2013; 9(1): 77-81.
- 76) Sarrafzadegan N, **Gharipour M**, Sadeghi M, Nouri F, Asgary S, Zarfeshani S. Differences in the prevalence of metabolic syndrome in boys and girls based on various definitions. *ARYA Atheroscler*. 2013; 9(1):70-6.
- 77) Saiedi M, Movahedi M, **Gharipour M**. Can the infusion of isotonic fluids or vasopressors prevent hemodynamic changes in cardiac surgery patients? *ARYA Atheroscler*. 2012; 8(3):161-3.

MOJGAN GHARIPOUR CURRICULUM VITAE

- 78) Shemirani H, Khosravi A, Hemmati R, **Gharipour M**. Body Mass Index or Microalbuminuria, which one is more important for the prediction and prevention of diastolic dysfunction in non-diabetic hypertensive patients? *Int J Prev Med*. 2012; 3(3): 211-20.
- 79) Khosravi AR, Rowzati M, **Gharipour M**, Fesharaki MG, Shirani S, Shahrokhi S, Jozan M, Khosravi E, Khosravi Z, Sarrafzadegan N. Hypertension control in industrial employees: findings from SHIMSCO study. *ARYA Atheroscler*. 2012; 7(4): 191-6.
- 80) Shemirani H, Hemmati R, Khosravi A, **Gharipour M**, Jozan M. Echocardiographic assessment of inappropriate left ventricular mass and left ventricular hypertrophy in patients with diastolic dysfunction. *J Res Med Sci*. 2012; 17(2): 133-7.
- 81) Movahedi M, Saiedi M, **Gharipour M**, Aghadavoudi O. Diagnostic performance and discriminative value of the serum ferritin level for predicting preterm labor. *J Res Med Sci*. 2012; 17(2): 164-6.
- 82) **Gharipour M**, Kelishadi R, Khosravi A, Shirani S, Masjedi M, Sarrafzadegan N. The impact of a community trial on the pharmacological treatment in the individuals with the metabolic syndrome: findings from the Isfahan Healthy Heart Program, 2001-2007. *Arch Med Sci*. 2012; 20; 8(6): 1009-17.
- 83) Saiedi M, Movahedi M, **Gharipour M**. Can the infusion of isotonic fluids or vasopressors prevent hemodynamic changes in cardiac surgery patients? *ARYA Atheroscler*. 2012; 8(3): 161-3.
- 84) Khosravi A, Toghianifar N, Sarrafzadegan N, **Gharipour M**, Azadbakht L. Salt intake, obesity, and pre-hypertension among Iranian adults: A cross-sectional study. *Pak J Med Sci*. 2012; 28(2): 297-302.
- 85) Sadeghi M, Golabchi A, Haghani P, **Gharipour M**, Naderi GA, Sarrafzadegan N. Can anti-streptokinase antibody predict myocardial infarction outcomes after streptokinase treatment? *J Pak Med Assoc*, 2012; 62 (3 Suppl 2): S31-34.
- 86) Sarrafzadegan N, **Gharipour M**, Sadeghi M, Khosravi AR, Tavassoli AA. Metabolic syndrome in Iranian elderly. *ARYA Atheroscler*. 2012; 7(4): 157-161.
- 87) Hashemi Jazi M, Esfahani MHN, Fesharaki M, Moulavi F, **Gharipour M**. Initial clinical outcomes of intracoronary infusion of autologous progenitor cells in patients with acute myocardial infarction. *ARYA Atheroscler*, 2012; 7(4): 162-167.
- 88) HashemiJazi M, Amirpour A, Zavvar R, Behjati M, **Gharipour M**. Predictive value of P-wave duration and dispersion in post coronary artery bypass surgery atrial fibrillation. *ARYA Atheroscler*. 2012; 8(2): 59-62.
- 89) Movahedi M, Saiedi M, **Gharipour M**, Aghadavoudi O. Diagnostic performance and discriminative value of the serum ferritin level for predicting preterm labor. *J Res Med Sci*. 2012; 17(2): 164-166.
- 90) Shemirani H, Hemmati R, Khosravi A, **Gharipour M**, Jozan M. Echocardiographic assessment of inappropriate left ventricular mass and left ventricular hypertrophy in patients with diastolic dysfunction. *J Res Med Sci*. 2012; 17(2): 133-137.
- 91) Shemirani H, Khosravi A, Hemmati R, **Gharipour M**. Body Mass Index or Microalbuminuria, Which One is More Important for the Prediction and Prevention of Diastolic Dysfunction in Non-Diabetic Hypertensive Patients? *Int J Pre Med*. 2012; 3(3):211-20.

MOJGAN GHARIPOUR CURRICULUM VITAE

- 92) Tavassoli A, **Gharipour M**, Toghianifar N, Sarrafzadegan N, Khosravi A, Zolfaghari B, Zarfeshani S. The impact of obesity on hypertension and diabetes control following healthy Lifestyle Intervention Program in a developing country setting. *J Res Med Sci*. 2011; 16 (Suppl 1): S368-76.
- 93) Hashemi Jazi M, Arasteh M, Shamsolketabi H, Tavassoli A, Nilforoush P, **Gharipour M**. Comparing Diagnostic Techniques of Magnetic Resonance Angiography (MRA) and Doppler Ultrasonography in Determining Severity of Renal Artery Stenosis. *ARYA Atheroscler*. 2011; 7(2):58-62.
- 94) **Gharipour M**, Kelishadi R, Toghianifar N, Tavassoli AA, Khosravi AR, Sajadi F, Sarrafzadegan N. Socioeconomic disparities and smoking habits in metabolic syndrome: evidence from Isfahan healthy heart program. *Iran Red Crescent Medical Journal*. 2011; 13(8):537-43.
- 95) Hemmati R, **Gharipour M**, Shemirani H, Khosravi A, Khosravi E. Urine albumin to creatinine ratio and echocardiographic left ventricular structure and function in patients with essential hypertension. *Am Heart Hosp J*. 2011 Winter; 9(2): 90-4.
- 96) Shirani S, **Gharipour M**, Khosravi A, Kelishadi R, Habibi HR, Abdalvand A, Sarrafzadegan N. Gender differences in the prevalence of hypertension in a representative sample of Iranian population: The Isfahan Healthy Heart Program. *Acta Biomedica*. 2011; 82(3): 223-9.
- 97) Bahonar A, Sarrafzadegan N, Kelishadi R, Shirani S, Ramezani MA, Taghdisi MH, **Gharipour M**. Association of socioeconomic profiles with cardiovascular risk factors in Iran: The Isfahan Healthy Heart Program. *Int J Pub Health*. 2011; 56(1):37-44.
- 98) Sarrafzadegan N, **Gharipour M**, Ramezani MA, Rabiei K, Zolfaghar B, Tavassoli AA, Boshtam M, Zarfeshani S, Khosravi A, Yousefi A. Metabolic syndrome and health-related quality of life in Iranian population. *J Res Med Sci*. 2011; 16(3): 254-61.
- 99) Sadeghi MM, **Gharipour M**, Nilforoush P, Shamsolkotabi H, Sadeghi HM, Kiani A, Sadeghi PM, Farahmand N. Influence of the timing of cardiac catheterization and amount of contrast media on acute renal failure after cardiac surgery. *J Res Med Sci*. 2011; 16(4): 502-8.
- 100) Khosravi AR, Pourmoghadas M, Ostovan M, Mehr GK, **Gharipour M**, Zakeri H, Soleimani B, Namdari M, Hassanzadeh M, Tavassoli AA, Ghaffari S, Khaledifar A, Roghani F, Khosravi MR, Sarami S, Kojouri J, Nori F, Khosravi E, Jozan M, Sarrafzadegan N. The impact of generic form of Clopidogrel on cardiovascular events in patients with coronary artery stent: results of the OPCES study. *J Res Med Sci*. 2011;16(5): 640-50.
- 101) Sadeghi MM, Arasteh M, **Gharipour M**, Nilfroush P, Shamsolketabi H, EtesampourA, Sadeghi FM, Kiani A, Sadeghi PM, Farahmand N. Evaluation of accuracy of Euroscore risk model in prediction of perioperative mortality after coronary bypass graft surgery in Isfahan. *J Res Med Sci*. 2011; 16(6): 787-92.
- 102) Tavassoli A, **Gharipour M**, Toghianifar N, Sarrafzadegan N, Khosravi A, Zolfaghari B, Zarfeshani S. The impact of obesity on hypertension and diabete control following healthy Lifestyle Intervention Program in a developing country setting. *J Res Med Sci*. 2011; 16(Suppl 1): S368-76.

MOJGAN GHARIPOUR CURRICULUM VITAE

- 103) HashemiJazi M, Arasteh M, Shamsolketabi H, Tavassoli A, Nilforoush P, **Gharipour M**. Comparing Diagnostic Techniques of Magnetic Resonance Angiography (MRA) and Doppler Ultrasonography in Determining Severity of Renal Artery Stenosis. *ARYA Atheroscler*. 2011; 7(2): 58-62.
- 104) Khosravi AR, Pourmoqhadas M, Ostovan M, Kiani Mehr G, **Gharipour M**, Zakeri H. The impact of generic form of Clopidogrel on cardiovascular events in patients with coronary artery stent: results of the OPCES study. *J Res Med Sci*. 2011; 16(5): 640-650.
- 105) Mirmohammad-Sadeghi M, Arasteh M, **Gharipour M**, Mirmohammad-Sadeghi P, Kiani A, Nilforoush P, Shamsolkotabi H, Farahmand N. Evaluation of accuracy of Euroscore risk model in prediction of perioperative mortality after coronary bypass graft surgery in Isfahan. *J Res Med Sci*. 2011; 16(6): 787-792.
- 106) Mirmohammad-Sadeghi M, **Gharipour M**, Mirmohammad-Sadeghi P, Saeidi M, Kiani A, Nilforoush P, Shamsolkotabi H, Farahmand N. Influence of the Timing of Cardiac Catheterization and the Amount of Contrast Media on Acute Renal Failure after Cardiac Surgery. *J Res Med Sci*. 2011; 16(4): 502-508.
- 107) **Gharipour M**, Kelishadi R, Toghianfar N, Mackie M, Noori F, Sarrafzadegan N. Pharmacological Treatment of Cardiovascular Risk Factors in Individuals with Metabolic Syndrome: Findings from Isfahan Healthy Heart Program. *African J Pharm Pharm*. 2011; 5(3): 311-316.
- 108) Tavassoli A, **Gharipour M**, Toghianifar N, Sarrafzadegan N, Khosravi A, Zolfaghari B, Zarfeshani S. The Impact of obesity on hypertension and diabetes control following healthy Lifestyle Intervention Program in a Developing Country setting. *J Res Med Sci*. 2011; 16(3): 254-261.
- 109) Sarrafzadegan N, **Gharipour M**, Ramezani A, Bahonar A, Rabiei K, Boshtam M, Yousefi A, Zarfeshani S. Metabolic syndrome and health related quality of life: Result from Isfahan Healthy Heart Program (IHHP). *J Res Med Sci*. 2011; 16(3): 254-261.
- 110) Khosravi A, Kianimehr G, Kelishadi R, **Gharipour M**, Sarrafzadegan N. The Impact of a 6-year comprehensive community trial on the awareness, treatment and control rates of hypertension in Iran: experiences from the Isfahan Healthy Heart Program. *BMC Cardiovascular Disorder*. 2010; 10:61.
- 111) Tavassoli AA, **Gharipour M**, Siadat ZD, Bahonar A, Sadry GH. Are obesogenic behavioral, socioeconomic and metabolic determinants different in Iranian men and women? *J Health Pop Nut*. 2010; 28(6): 602-9.
- 112) Baghaei AM, Sarrafzadegan N, Rabiei K, **Gharipour M**, Tavasoli AA, Shirani S, Bahonar A, Davarpanah AH, Ramezani MA, Kelishadi R. How effective are strategies for Non Communicable Disease Prevention and Control on High Risk Population in a Developing Country? *Arch Med Sci*. 2010; 6(1): 24-31.
- 113) Bahonar A, Sarrafzadegan N, Kelishadi R, Shirani S, Ramezani MA, Taghdisi MH, **Gharipour M**. Association of socioeconomic profiles with cardiovascular risk factors in Iran: The Isfahan Healthy Heart Program. *Int J Pub Health*. 2011; 56(1): 37-44.
- 114) Mirmohammad Sadeghi M, Etesampour A, **Gharipour M**, Shariat Z, Nilforoush P, Saeidi M, Mackie M, Mirmohamad Sadeghi F. Early chest tube removal after coronary artery bypasses graft surgery. *North American Journal of Medical Sciences*. 2009; 1(7): 333-337.

MOJGAN GHARIPOUR

CURRICULUM VITAE

- 115) Mousavi E, **Gharipour M**, Tavassoli A, Sadri GH, Sarrafzadegan N. Multiparty and Risk of Metabolic Syndrome: Isfahan Healthy Heart Program. *Metab Syndr Relat Disord*. 2009; 7(6): 519-24.
- 116) Mirmohammad Sadeghi M, Etesampour A, Gharipour M. Relationship between serum lactate levels and morbidity outcomes in cardiovascular patients after CABG. *J Surg Pak*. 2008; 13(2): 88-91.
- 117) Kelishadi R, **Gharipour M**, Sadri GH, Tavasolli AA, Amani A. Cardiovascular disease risk factors, metabolic syndrome and obesity in an Iranian population. *East Mediterr Health J*. 2008; 14(5): 84-93.
- 118) Asgary S, Naderi GH, **Gharipour M**. Measuring Autoantibody against Modified LDL in Cardiovascular Patients. *Cell Tissue*. 2007; 7(1): 18-25.
- 119) Asgary S, Aghaei A, Naderi GH, Kelishadi R, **Gharipour M**. Effect of Ramadan fasting on lipid peroxidation, serum lipoproteins and fasting blood sugar. *J Isl Acad Sci*. 2000; 13(1): 35-38.

E. NATIONAL ARTICLES:

- 1) Kazemi A, Sadeghi M, Hashemi M, Heidari R, **Gharipour M**, Golabchi A, Sarrafzadegan N. Evaluating the relation between metabolic syndrome and its components with low ankle to brachial index in an Iranian population. *J Isf Med Sci*. 2011; 28(122): 1-9.
- 2) Mirmohammadsadeghi M. Etesami Pour A, Mirmohammad Sadeghi FS, **Gharipour M**, Saeedi M, Nilfroush P, Shariat Z. Is Euro scoring a good model to predict mortality in Iranian patients before coronary bypass surgery? *J Isf Med Sci*. 2011; 28(117): 882-889.
- 3) **Gharipour M**, Akhavan Tabib A, Toghianifar N, Tavassoli AA, Gharipour A, Sarrafzadegan N. The pattern of pharmacological treatment in subjects with metabolic syndrome: findings from Isfahan Healthy Heart Program. *J Isf Med Sci*. 2011; 29(138): 562-570.
- 4) Mirmohammad Sadeghi M. Etesampour A, **Gharipour M**, Saeedi M, Kiani A, Nilfroush P, Shamsolkotabi H, Farahmand N. The Association between Serum Lactate Level and Post CABG Complications in Cardiac Patients. *J Isf Med Sci*. 2011; 29(128): 1-8.
- 5) Mirmohammad-Sadeghi M, Etesampour A, Shariat Z, **Gharipour M**, Saeidi M, Nilfroush P, Mirmohammad-Sadeghi F. Early chest tube removal after coronary artery bypass graft surgery. *J Isf Med Sci*. 2010; 28(104): 25-33.
- 6) Bahonar A, Shahnam M, AsadiLari M, Boshtam, M, **Gharipour M**, Sarrafzadegan N. Cardiovascular risk factors in a population of labor in the Isfahan. *Iran Occup health J*. 2010; 7(1): 4-10.
- 7) Akhtar HJ, Sarrafzadegan N, Mohammadifard N, Kelishadi R, Siadat ZD, **Gharipour M**. Is there difference between dietary habits in hypertensive, hyperlipidemics, obese, smokers and the normal population? *ARYA Atheroscler*. 2008; 4(3): 112-120.
- 8) Bigdelian H, **Gharipour M**. Postoperative treatment with Amiodarone prevents paroxysmal Arterial Fibrillation after Coronary Artery Bypass Grafting. *ARYA Atheroscler*. 2008; 4(4).

MOJGAN GHARIPOUR CURRICULUM VITAE

- 9) Bigdelian H, **Gharipour M.** Comparison of retrograde-antograde versus retrograde cardioplegia: randomized trial in patients with coronary artery bypasses grafting. *ARYA Atheroscler.* 2008; 4(4): 1-4.
 - 10) Naderi GH, Asgary S, **Gharipour M.** Taher M, Khosravi E, Nikkhoo N. Antioxidant effect of Peper Nigrum on hepatocyte membrane and LDL oxidation and nonenzymatic glycosylation of hemoglobin. *Hakim Journal.* 2007; 10(4): 11-16.
 - 11) Sadeghi M, Ramezani J, Sanei H, Rabiei K, **Gharipour M.** Toghianifar N. Adherence to evidence-based therapies and modifiable risk factors in patients with coronary artery disease - the HLCP project. *ARYA Atherosclerosis.* 2006; 2(3): 147-151.
 - 12) Asgary S, **Gharipour M.** Naderi GH. In vitro effect of Nicotine and Cotinine on the susceptibility of LDL oxidation and Hemoglobin glycosilation. *J Qazvin Med Health Serv.* 2006; 9(2): 20-26.
 - 13) **Gharipour M.** Boshtam M, Baghaie AM, Khosravi A. Prevalence of metabolic syndrome in Iranian population by sex and residency. *Birjand J Med Sci.* 2006; 13(3): 56-62.
 - 14) Asgary S, **Gharipour M.** Naderi GH, Khosravi A, Hashemi M. Autoantibody against oxidized low-density Lipoproteins in patients with coronary artery disease. *Diab Lipid Dis.* 2005; 4(2): 15-21.
 - 15) Asgary S, Naderi GH, **Gharipour M.** Effect of Amirkabiriaodorastissiam Mozaffarian on the Development and progression of fatty streak on hypercholesteromic rabbits. *Diab Lipid dis.* 2004; 3(1): 83-8.
 - 16) Asgary S, Naderi GH, **Gharipour M.** The effect of some flavonoids on in vitro Non-Enzymatic Glycosylation of proteins. *Behbood J.* 2004; 8(9): 1-9.
 - 17) Naderi GH, Boshtam M, Sarrafzadegan N, **Gharipour M.** New risk factors for cardiovascular disease in Isfahanain urban community. *J Kerman Uni.* 2003; 1(11): 28-35.
 - 18) Asgary S, Naderi GH, Ghasemi N, **Gharipour M.** Kelishadi R, Bashardoost N. Inhibitory effects of polyphenolic extracts of *Betulapendula*, *Saliva hydrangea* and *Crataeguscurvisepala*, as well as Vitamin C on the extent of glycosylation of Albumin, Insulin and Hemoglobin. *J Isf Med Sci.* 2003; 8(3): 75-81.
 - 19) **Gharipour M.** Mohamadifard N, Asgary S, Naderi GH. The prevalence of obesity and cardiovascular risk factors in Isfahan. *J Qazvin Uni Med Health Serv.* 2003; 7(2) 26: 53-64.
 - 20) Asgary S, Naderi GH, Ghanadian A, **Gharipour M.** Protective effect of *Achilleamillefolium*, *Crataeguscurvisepala* and *Matricariachamomilla* on oxidative hemolysis of human erythrocytes and –SH capacity. *J Med Plants.* 2003; 2(6): 41-48.
 - 21) **Gharipour M.** Moshtaghi AA, Movahedian A. Effects of gallium on bilirubin and Aminotransferases in rats. *Behbood J.* 2003; 6(4): 10-16.
 - 22) Naderi GH, Asgary S, **Gharipour M.** In vitro effect of nicotine and cotinine on the susceptibility of LDL oxidation and hemoglobin glycosylatoin. *Mol Cell Bioch.* 2003; 246:117-120.
 - 23) Moshtaghi AA, **Gharipour M.** Movahedian A. Study of the effects of gallium on liver function. *Urmia Med J.* 2001; 12(3): 197-205.
-

MOJGAN GHARIPOUR CURRICULUM VITAE

F. INTERNATIONAL CONGRESSES:

- 1) Moderator of panel of metabolic syndrome in th12th Middle East Cardiovascular Congress and 5th congress of clinical cases in complex cardiovascular therapeutic held on 21 October, 2021.
- 2) Moderator of panel of metabolic syndrome in th12th Middle East Cardiovascular Congress and 5th congress of clinical cases in complex cardiovascular therapeutic held on 4 November, 2020.
- 3) **Gharipour M.** Epigenetic modification, aging and metabolic syndrome. 13th Middle East Cardiovascular Congress and 6th Congress of Clinical Cases in Complex Cardiovascular Therapeutics. 2021; Oct 21-24, Shiraz, IRAN.
- 4) **Gharipour M.** Effect of Single Nucleotide Polymorphisms in SEPS1 and SELPP1 on expression in the protein level in metabolic syndrome in subjects with cardiovascular disease. 88th EAS 2020 virtual Congress, 2020; Oct, 04-07, Geneva, Switzerland.
- 5) **Gharipour M.** Association of Selenoprotein S expression and its variants with metabolic syndrome in subjects with cardiovascular disease. Diabetes Technology & Therapeutics. 20 (1) A142-A142.
- 6) **Gharipour M.** Critical role of microrna-33 in metabolic syndrome. World Bio Summit & Expo 2015, Nov 02-04, Dubai, UAE.
- 7) **Gharipour M.** Socioeconomic determinates and metabolic syndrome: Results from the Isfahan Healthy Heart Program. The 1th NCD Congress UAE. 2014; Jan 9 -11, Dubai, UAE.
- 8) **Gharipour M.** The metabolic syndrome and associated lifestyle factors among the Iranian population. The first NCD congress UAE. 2014; Jan 09-10, Dubai, UAE.
- 9) **Gharipour M.** Pharmacological treatment of cardiovascular risk factors in individuals with metabolic syndrome, before and after interventions: findings from the Isfahan Healthy Heart Program. 21th European meeting on hypertension. 2011; June 17-21, Milan, Italy.
- 10) Toghianifar N, Kelishadi R, **Gharipour M.** Nouri F. Smoking cessation advice among diabetic patients in a population-based sample of Iranian adults (IHHP). International Conference on Early Disease Detection and Prevention. 2010; Feb 25-28, Munich, Germany.
- 11) **Gharipour M.** Pharmacological treatment of cardiovascular risk factors in individuals with metabolic syndrome: findings from the Isfahan Healthy Heart Program. The 20th European meeting on hypertension. 2010; Jun 18-21, Oslo, Norway.
- 12) **Gharipour M.** Metabolic syndrome patient compliance with drug treatment (Isfahan Healthy Heart Study). World congress of cardiology scientific sessions. 2010; June 16 –19, Beijing, China.
- 13) **Gharipour M.** Sarrafzadegan N, Siadat Z, Maghroun M, Abdalvand A. Metabolic syndrome epidemiology based on socioeconomic status: cross sectional study among Iranian adult population (IHHP Study). The XV International symposium on atherosclerosis. 2009; June 14-18, Boston, USA.

MOJGAN GHARIPOUR CURRICULUM VITAE

- 14) **Gharipour M**, Sarrafzadegan N. Effect of smoking habits on components of metabolic syndrome in non-diabetic men: The Isfahan healthy heart program. The 3rd International Congress on Prediabetes and the Metabolic Syndrome. 2009; Apr 01-04, Nice, France.
- 15) Sarrafzadegan. **Gharipour M**. Obesity, socioeconomic and metabolic determinants in Iranian population. The 3rd International Congress on prediabetes and the Metabolic Syndrome. 2009; Apr 01-04, Nice, France.
- 16) Sarrafzadegan N, **Gharipour M**. Number of children and risk of metabolic syndrome in Iranian women. The 3rd International Congress on prediabetes and the Metabolic Syndrome. 2009; Apr 01-04, Nice, France.
- 17) **Gharipour M**, Sarrafzadegan N. Socioeconomic status and metabolic syndrome in Iranian population (IHHP study). The 3rd International Congress on Prediabetes and the Metabolic Syndrome. 2009; Apr 01-04, Nice, France.
- 18) **Gharipour M**, Kelishadi R, Baghaie AM, Yazdani M. Pharmacological treatment, lifestyle modification and awareness in coronary artery and cerebrovascular disease. 18th Scientific Meeting of the European Society of Hypertension 22nd scientific meeting of the international society of hypertension. 2008; June 14-19, Berlin Germany.
- 19) Asgary S, Naderi GH, **Gharipour M**. The antioxidant activity of the essential oils of Iranian conifers on red blood cell. The 6th International symposium on atherosclerosis. 2003; Sep 28–October 2, Kyoto, Japan.
- 20) Asgary S, Naderi GH, **Gharipour M**. The effect of opium addiction on levels of fibrinogen, factor VII and CRP. Sixth International symposium on atherosclerosis. 2003; Sep 28-October 02, Kyoto, Japan.
- 21) Asgary S, Naderi GH, **Gharipour M**. Auto antibody against oxidized low-density lipoproteins in patients with coronary artery disease. Sixth International symposium on atherosclerosis. 2003; September 28 - October 2, Kyoto, Japan.
- 22) Asgary S, Naderi GH, **Gharipour M**. The effect of opium addiction on levels of fibrinogen, factor VII and CRP. 15th international postgraduate course on cardiovascular disease. 2003; Feb 10-14, Davos, Switzerland.
- 23) Asgary S, Naderi GH, **Gharipour M**. Study's antioxidant effect of some Iranian popular spices on LDL oxidation. 15th international postgraduate course on cardiovascular disease. 2003; Feb 10-14, Davos, Switzerland.
- 24) Naderi GH, Asgary S, Dehghani A, Azali SH, **Gharipour M**. The effect of opium addition on the plasma levels of fibrinogen factor VII and CRP. The 73th EAS Congress. 2002; July 7-10, Salzburg, Austria.
- 25) Asgary S, Naderi GH, Emami A, Shams Ardekani AM, Keshner T, **Gharipour M**. Antioxidant effect of the essential oils of Iranian conifers and vitamin c on LDL oxidation. The 73th EAS Congress. 2002; July 07-10, Salzburg, Austria.
- 26) Asgary S, Naderi GH, **Gharipour M**. Antioxidant effect of flavonoids on the susceptibility of LDL oxidation. A9/154. 2001; Canada.
- 27) Asgary S, Naderi GH, **Gharipour M**. Inhibition of collagen and ADP-induced platelet aggregation by natural products. A9/147, 2001; Canada.

MOJGAN GHARIPOUR CURRICULUM VITAE

- 28) Asgary S, Naderi GH, **Gharipour M.** Antioxidant effect of flavonoids on the susceptibility of LDL oxidation. The first WHE global conference on cardiovascular clinical trials.2001; Nov 21-23, Hong Kong China.
- 29) Asgary S, Naderi GH, **Gharipour M.** The effect of nicotine and cotinine on the susceptibility of LDL oxidation. The first WHE global conference on cardiovascular clinical trials.2001; Nov 21-23, Hong Kong China.
-

MOJGAN GHARIPOUR CURRICULUM VITAE

G. NATIONAL CONGRESSES

- 1) Gharipour M.** Personalized medicine and metabolic syndrome. The 3st International Congress of personalized medicine, Feb 2019; Tehran, Iran.
- 2) Gharipour M.**, Sadeghi M, Salehi M, Behmanesh M. Association of expression of selenoprotein P in mRNA and protein levels with metabolic syndrome in subjects with cardiovascular disease: Result of the Selenegene study. The 1st International Congress of personalized medicine, Feb 2016; Tehran, Iran.
- 3) Gharipour M.**, Maghroon M, Tavasolli AA, Sarrafzadegan N, Mackie M. Social determinants and smoking in patients with metabolic syndrome in Iranian population (IHHP study). The 1st International Congress on Tobacco Control, June 2009; Kish Island, Iran.
- 4) Gharipour M.**, Kelishadi, R, Baghaie AM, Boshtam M, Rabeie K. Prevalence of metabolic syndrome in an Iranian population. The 1st Iranian Congress of metabolic syndrome, June 2008; Tabriz, Iran.
- 5) Gharipour M.**, Kelishadi R, Baghaie AM, Yazdani M. The Association of smoking and components of the metabolic syndrome in non-diabetic patients. The 1st Iranian congress of metabolic syndrome, June 2008; Tabriz, Iran.
- 6) Sarrafzadegan N, Gharipour M.**, Siadat DZ, Tavasolli AA, Sajadi F. Are obesogenic behavioral, socioeconomic and metabolic determinants different in Iranian men and women? The 1st Iranian Congress of metabolic syndrome. June 2008; Tabriz, Iran.
- 7) Asgary S, Naderi GH, Gharipour M.** Fibrinolytic effects of some herbs. Gharipour M, Kelishadi R, Baghaie AM, Yazdani M. The association of smoking and components of the metabolic syndrome in non-diabetic patients. The 1st congress of tobacco and health. Dec 2008; Bandar Abbas, Iran.
- 8) Gharipour M.**, Asgari S, Naderi GH. Evaluating the prevalence of obesity and CVD risk factors in Isfahan population. The 6th Iranian congress of Biochemistry. Jan 2004; Ahwaz, Iran.
- 9) Asgary S, Gharipour M.**, Naderi GH. Autoantibody against oxidized low-density lipoproteins in parents with coronary artery disease. The 6st Iranian congress of biochemistry. Jan 2004; Ahwaz, Iran.
- 10) Asgary S, Naderi GH, Gharipour M.** Dose the rate of peroxidasion lipid differs in addict person and non-addict person? The 7st seminar on toxicology and poisoning. Isfahan University of Medical Sciences. May 2002; Isfahan, Iran,
- 11) Gharipour M.**, Moshtaghi AA, Movahedian A. Effect of gallium on liver function. The 6st Iranian congress of biochemistry, Iran University of Medical Sciences. May 2002; Tehran, Iran.
- 12) Gharipour M.**, Moshtaghi AA, Movahedian A. Effect of gallium on alkaline phosphates. The 5th Iranian congress of biochemistry, Tehran University of Medical Sciences. May 1999; Tehran, Iran.

H. BOOKS (PUBLISHED):

- **Gharipour M.** Prevention of recurrent heart attacks and stroke, Isfahan University Press (2005). ISBN: 964-6329-87.
-

MOJGAN GHARIPOUR CURRICULUM VITAE

I. LABORATORY SKILLS:

- 1) **Molecular techniques:** DNA and RNA extraction, flow cytometry, electrophoresis PCR, Real-time PCR restriction fragment length polymorphism, array and sequencing-based methods for measurement polymorphisms on DNA,
 - 2) **Epigenetics techniques:** array and sequencing-based methods for measurement DNA methylation, quality control process, pyrosequencing PCR, designing primer for specific methylated region and probes for global methylation.
 - 3) **Bio-banking:** storage of bio-samples, and computer-based program for biobanks.
 - 4) **Biochemical laboratory techniques:** ELISA, western blot, sub-cellular fractionation with ultra-centrifuge.
 - 5) **Bioinformatics:** network and systems biology, gene enrichment analysis and GEO data analysis.
 - 6) **Biomedical Research:** methodology, medical writing, medical statistics (SPSS).
-

J. EMPLOYMENT:

- 1) 2021 to date: Manager of research and clinical laboratories of Isfahan Cardiovascular Research Institute
 - 2) **2020 to date:** Section editor of Journal of Archive of Medical Sciences
 - 3) **2020 to date:** Manager of bio-bank of Isfahan Cardiovascular Research Institute
 - 4) **2018 to 2019:** Deputy of research, Cardiac Rehabilitation Research Center, Cardiovascular Research Institute
 - 5) **2017 to 2019:** Associate editor of ARYA Atherosclerosis Journal
 - 6) **2014 to date:** Head of genetic and epigenetics studies unit of Cardiovascular Research Institute
 - 7) **2011 to 2017:** Managing editor of ARYA Atherosclerosis Journal
 - 8) **2006 to 2012:** Technical editor of ARYA Atherosclerosis Journal
 - 9) **2006:** Junior researcher in basic science department
-

K. PROFESSIONAL MEMBERSHIPS:

- 1) 2019 to date: Member of international epigenetics society
- 2) 2018 to 2119: Member of American human genetic society
- 3) 2016 to date: Member of European atherosclerosis society
- 4) 2012 to date: Member of committee on publication ethics (COPE)

MOJGAN GHARIPOUR CURRICULUM VITAE

K. SCIENTIFIC REVIEWER IN:

- 1) ARYA Atherosclerosis Journal
- 2) International Journal of Cardiology
- 3) Journal of Archives of Medical Science
- 4) BMC Public Health
- 5) Canadian Journal of Medicine
- 6) Diabetes Research and Clinical Practice Journal
- 7) Open Journal of Internal Medicine
- 8) Nutrition
- 9) African Journal of Pharmacy and Pharmacology
- 10) Journal of Research in Medical Sciences
- 11) BMC in Cardiovascular Disease
- 12) British Journal of Medicine and Medical Research
- 13) Surgery: Current Research
- 14) Advance in Biomedical Researches
- 15) Education and Health Promotion

L. PROFESSIONAL EXPERIENCE:

Workshops attended:

- 1) Meta-analysis, Isfahan University of Medical Sciences, 2019, Isfahan, Iran
- 2) Data analysis of micro array data, (Royan), 2019; Isfahan, Iran.
- 3) Data analysis of next generation sequencing, introduction, application, challenges, and methods of data analysis, (OMICS), 2017; Isfahan, Iran.
- 4) Clear and successful scientific writing, national institute for medical development, (Nimad), 2017; Isfahan, Iran.
- 5) Scientific peer reviewing of biomedical health science journal manuscripts, National Institute for Medical Development, (Nimad), 2016; Tehran, Iran.

MOJGAN GHARIPOUR

CURRICULUM VITAE

- 6) Advanced workshop on flow cytometry, Applied Physiology Research Center, Isfahan University of Medical Sciences, 2013; Isfahan, Iran.
- 7) Systematic review, 2013; Isfahan University of Medical Sciences. 2013; Isfahan, Iran.
- 8) Advanced medical writing held by Isfahan University of Medical Sciences. 2013; Isfahan, Iran.
- 9) Workshop on western blotting, Pharmacy School, Isfahan University of Medical Sciences, 2013; Isfahan, Iran.
- 10) Advanced medical writing held by the Isfahan Cardiovascular Research Center and McGill University 2008: Isfahan, Iran.
- 11) Knowledge Transfer, Isfahan University of Medical Sciences, 2010; Isfahan, Iran.
- 12) Open journal system held by Farzanegan Radandish Company, 2009; Isfahan, Iran.
- 13) Paper evaluation-peer review held by the Royan Institute, 2008; Tehran, Iran.
Advanced medical writing held by the Isfahan Cardiovascular Research Center and MC Gill University, 2008; Isfahan, Iran.
- 14) Training course of DNA extraction, PCR, allele specific amplification and detection of Sickle Cell Anemia by ARMS, Electrophoresis (Agarose gel, poly acrylamide gel, silver staining, thorium bromide), sequencing, restriction fragment polymorphism. College of Medicine & Health Sciences, Sultan Qaboos University, 2006; Muscat, Oman.
- 15) Medical writing workshop held by Isfahan University of Medical Sciences, 2005; Isfahan, Iran.
- 16) National Workshop on Secondary Prevention of Myocardial Infarction & Stroke, and Management of cardiovascular risk held by WHO and Isfahan Cardiovascular Research Center, Isfahan, Iran 2005.
- 17) National workshop on secondary prevention of myocardial infarction & stroke, and management of cardiovascular risk held by WHO and Isfahan Cardiovascular Research Center, 2005; Isfahan, Iran.
- 18) Advanced workshop on clinical trials, Isfahan University of Medical Sciences, and 2004; Isfahan, Iran.
- 19) Workshop on statistics, Isfahan University of Medical Sciences 2004; Isfahan, Iran.
- 20) Workshop on research methodology held by the Isfahan University of Medical Sciences 2003; Isfahan, Iran.
- 21) Workshop on strategic planning held by research deputy, Isfahan University of Medical Sciences, 2003; Isfahan, Iran.

N. INTERNATIONAL RESEARCH PROJECTS:

- 1) Isfahan Twins registry with collaboration international Twin's society.
- 2) Identification of genes for early myocardial infarction in Iran (Collaborating with Yale University).
- 3) Secondary prevention of myocardial infarction and stroke and management of cardiovascular risk (A multi-centric study with the collaboration of World Health Organization).
- 4) Effects of selenium supplementation on selenoprotein P and S genes expression in protein and mRNA levels in subjects with cardiovascular disease: study protocol for a double-blind randomized controlled trial.

MOJGAN GHARIPOUR CURRICULUM VITAE

- 5) Five-year incidence of non-communicable diseases and their risk factors in twins and multiplies in Isfahan
-

O. NATIONAL RESEARCH PROJECTS:

- 1) Five-year incidence of non-communicable diseases and their risk factors in twins and multiplies in Isfahan (Local project).
 - 2) Association of single nucleotide polymorphisms in salt taste receptor genes with dietary salt intake and blood pressure among Iranian young adult's population (Local project).
 - 3) Association study between polymorphisms in the APOA4 gene and premature myocardial infarction in Iranian population healthy lifestyle for high risk groups (National project).
 - 4) Healthy lifestyle for cardiovascular patients (National project).
 - 5) Evaluation of new risk factor of cardiovascular disease Apo-A and Apo-B, before and after intervention in Isfahan (Local project).
 - 6) Determination the effect of different method of using opium and duration use on cardiovascular risk factors (Local project).
 - 7) Evaluating the role of LDL oxide on restenosis after doing angioplasty (Local project)
 - 8) Evaluation of new risk factors of cardiovascular disease Apo A and Apo B, before and after intervention Isfahan (Local project).
 - 9) Evaluation of new risk factor of cardiovascular disease, uric acid, fibrinogen, factor VII, Lpa, MDA, Insulin, oxidative stress, before and after intervention Isfahan (Local project).
 - 10) Evaluation the efficacy and side effect of Iranian Levostatin and other type of this drug (Local project).
 - 11) Determination the correlation between plasma level of Lpa and restenosis after coronary angioplasty (Local project).
 - 12) Considering the knowledge, attitude and practice of Isfahan population regarding consumption herbal medicines (Local project).
 - 13) Following up the ex-smokers in one year after the international antismoking contest quit and win 1998 (Local project).
-